Piecing the Puzzle Together in the Diagnosis and Management of PF-ILD

Target Audience

This activity has been designed to meet the educational needs of pulmonologists, radiologists, and pathologists. It may also be of benefit to primary care physicians, PAs, nurse practitioners, nurses, pharmacists, fellows, residents, and other healthcare professionals who care for patients with chronic, progressive fibrosing lung disease (PF-ILD).

Program Overview

Interstitial lung disease (ILD) can be progressive and severely debilitating. Clinicians need to understand the key diagnostic features of ILD and be able to distinguish among different types, particularly those associated with chronic fibrosis and a progressive phenotype, including inflammatory connective-tissue diseases, idiopathic nonspecific interstitial pneumonia (iNSIP), chronic hypersensitivity pneumonitis (HP), and unclassified ILD, which can lead to increased morbidity and mortality. Lack of knowledge regarding CF-ILD with a progressive phenotype, as well as deficits in understanding of disease management, available recommendations, and recent clinical research, are significant barriers to improving outcomes and quality of life for patients. The goal of this activity is to improve recognition and differential diagnosis of ILD subtypes at risk of chronic fibrosis, and to improve management of these patients through integration of traditional and newer therapy options into routine practice.

Learning Objectives

Upon completion of this activity, participants should be better able to:

Distinguish among PF-ILD subtypes and the pathophysiology associated with increased risk of progression
Identify patients with PF-ILD at increased risk of progression who should be closely monitored
Evaluate evidence from recent and ongoing clinical trials for its impact on the management of PF-ILD